Eli Lilly tops quarterly expectations, raises forecast

Eli Lilly and Co. raised its 2019 forecast after a jump in sales from the diabetes treatment Trulicity helped push the drugmaker to a better-than-expected second quarter.

Revenue from the once-weekly treatment climbed 32% to top $1 billion, helping Lilly counter declines from top sellers such as the insulin Humalog and the erectile dysfunction drug Cialis.

Overall, Indianapolis-based Lilly earned $1.33 billion in the three-month period that ended June 30. That compares to a loss of about $260 million in last year’s quarter, when acquisition charges weighed on results.

Earnings, adjusted for amortization and research and development costs, totaled $1.50 per share. Analysts expected, on average, adjusted earnings of $1.46 per share, according to Zacks Investment Research.

Lilly’s revenue came in nearly flat at $5.64 billion.

The drugmaker now expects adjusted earnings to range from $5.67 to $5.77 per share up from its previous forecast for $5.60 to $5.70 per share.

Analysts expect, on average, earnings of $5.67 per share, according to FactSet.

Lilly shares were down 11 cents in morning trading, to $108.16 each.

The stock has fallen 6% since the beginning of the year, but are up 13% in the last 12 months.

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.